Comparing the joint effect of arsenic exposure, cigarette smoking and risk genotypes of vascular endothelial growth factor on upper urinary tract urothelial carcinoma and bladder cancer

Journal of Hazardous Materials

Volumn 262, Issue , 2013, Pages 1139-1146

  Wang, Yuan Hung ^a,b,c   Yeh, Shauh Der ^d,e   Wu, Meei Maan ^f   Liu, Chi Tung ^a   Shen, Cheng Hung ^g   Shen, Kun Hung ^h,i   Pu, Yeong Shiau ^j   Hsu, Ling I ^k   Chiou, Hung Yi ^a   Chen, Chien Jen ^k  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^f NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^g CHIA YI CHRISTIAN HOSPITAL   (Taiwan)

^h CHI MEI MEDICAL CENTER   (Taiwan)

ⁱ CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

^j NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^k GENOMICS RESEARCH CENTER   (Taiwan)

more..

Author keywords

Arsenic; Bladder cancer; Cigarette smoking; Upper urinary tract; Urothelial carcinoma; Vascular endothelial growth factor

Indexed keywords

ARSENIC; DISEASES; ENDOTHELIAL CELLS; GENES;

BLADDER CANCERS; CIGARETTE SMOKING; URINARY TRACT; UROTHELIAL CARCINOMA; VASCULAR ENDOTHELIAL GROWTH FACTOR;

RISK PERCEPTION;

ARSENIC; VASCULOTROPIN;

ARSENIC; CANCER; COMPARATIVE STUDY; GENOTYPE-ENVIRONMENT INTERACTION; HEALTH RISK; HISTOPATHOLOGY; POLLUTION EFFECT; POLLUTION EXPOSURE; SMOKING; TEMPORAL PERIOD; VASCULAR PLANT;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; DISTANT METASTASIS; ENVIRONMENTAL EXPOSURE; FEMALE; GENOTYPE; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; TRANSITIONAL CELL CARCINOMA; UPPER URINARY TRACT UROTHELIAL CARCINOMA;

95% CI; 95% CONFIDENCE INTERVAL; ARSENIC; BLADDER CANCER; CIGARETTE SMOKING; HARDY-WEINBERG EQUILIBRIUM; HWE; LD; LINKAGE DISEQUILIBRIUM; ODDS RATIO; OR; PAHS; PCR-RFLP; POLYCYCLIC AROMATIC HYDROCARBONS; POLYMERASE CHAIN REACTION-RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REACTIVE OXYGEN SPECIES; ROS; SINGLE NUCLEOTIDE POLYMORPHISM; SNP; UC; UPPER URINARY TRACT; UROTHELIAL CARCINOMA; VASCULAR ENDOTHELIAL GROWTH FACTOR; VEGF;

AGED; ARSENIC; CARCINOMA; CASE-CONTROL STUDIES; ENVIRONMENTAL EXPOSURE; FEMALE; GENOTYPE; HOSPITALIZATION; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; RESIDENCE CHARACTERISTICS; RISK; RISK FACTORS; SMOKING; URINARY BLADDER NEOPLASMS; UROTHELIUM; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84887617414     PISSN: 03043894     EISSN: 18733336     Source Type: Journal    
DOI: 10.1016/j.jhazmat.2012.08.056     Document Type: Article

References (47)

1. Bureau of Health Promotion, Department of Health, Taiwan, Republic of China. Cancer Registry Annual Report, 2010. Available at: http://crs.cph.ntu.edu.tw/crsc/annual.html.
2. Wang Y.H., Yeh S.D., Shen K.H., Shen C.H., Juang G.D., Hsu L.I., Chiou H.Y., Chen C.J. A significantly joint effect between arsenic and occupational exposures and risk genotypes/diplotypes of CYP2E1, GSTO1 and GSTO2 on risk of urothelial carcinoma. Toxicol. Appl. Pharmacol. 2009, 241:111-118.
3. Chou Y.H., Hung C.H. Unusual clinical presentation of upper urothelial carcinoma in Taiwan. Cancer 1999, 85:1342-1344.
4. Tan L.B., Chang L.L., Cheng K.I., Hung C.H., Kwan A.L. Transitional cell carcinomas of the renal pelvis and the ureter: comparative demographic characteristics, pathological grade and stage and 5-year survival in a Taiwanese population. BJU Int. 2008, 103:312-316.
5. Colin P., Koenig P., Ouzzane A., Berthon N., Villers A., Biserte J., Rouprêt M. Environmental factors involved in carcinogenesis of urothelial cell carcinomas of the upper urinary tract. BJU Int. 2009, 104:1436-1440.
6. Hsu L.I., Chiu A.W., Huan S.K., Chen C.L., Wang Y.H., Hsieh F.I., Chou W.L., Wang L.H., Chen C.J. SNPs of GSTM1, T1, P1, poxide hydrolase and DNA repair enzyme XRCC1 and risk of urinary transitional cell carcinoma in south-western Taiwan. Toxicol. Appl. Pharmacol. 2008, 228:144-155.
7. Liaw Y.P., Chen C.J., Lee W.C., Hsu S.Y. The construction and use of the electric atlas of cancer mortality and incidence in Taiwan. Taiwan J. Public Health 2003, 22:227-236.
8. Chiou H.Y., Hsueh Y.M., Liaw K.F., Horng S.F., Chiang M.H., Pu Y.S., Lin J.S., Huang C.H., Chen C.J. Incidence of internal cancers and ingested inorganic arsenic: a seven-year follow-up study in Taiwan. Cancer Res. 1995, 55:1296-1300.
9. Chiou H.Y., Chiou S.T., Hsu Y.H., Chou Y.L., Tseng C.H., Wei M.L., Chen C.J. Incidence of transitional cell carcinoma and arsenic in drinking water: a follow-up study of 8102 residents in an arseniasis-endemic area in northeastern Taiwan. Am. J. Epidemiol. 2001, 153:411-418.
10. Strope S.A., Montie J.E. The causal role of cigarette smoking in bladder cancer initiation and progression, and the role of urologists in smoking cessation. J. Urol. 2008, 180:31-37.
11. Karagas M.R., Park S., Warren A., Hamilton J., Nelson H.H., Mott L.A., Kelsey K.T. Gender, smoking, glutathione-S-transferase variants and bladder cancer incidence: a population-based study. Cancer Lett. 2005, 219:63-69.
12. Pelucchi C., Bosetti C., Negri E., Malvezzi M., La Vecchia C. Mechanisms of disease: the epidemiology of bladder cancer. Nat. Clin. Pract. Urol. 2006, 3:327-340.
13. Zeegers M.P., Tan F.E., Verhagen A.P., Weijenberg M.P., van den Brandt P.A. Elevated risk of cancer of the urinary tract for alcohol drinkers: a meta-analysis. Cancer Causes Control 1999, 10:445-451.
14. Jiang X., Castelao J.E., Groshen S., Cortessis V.K., Ross R.K., Conti D.V., Gago-Dominguez M. Alcohol consumption and risk of bladder cancer in Los Angeles county. Int. J. Cancer 2007, 121:839-845.
15. Pinto A., Redondo A., Zamora P., Castelo B., Espinosa E. Angiogenesis as a therapeutic target in urothelial carcinoma. Anticancer drugs 2010, 21:890-896.
16. Yang S., Wu X., Luo C., Pan C., Jun J. Expression and clinical significance of hepaCAM and VEGF in urothelial carcinoma. World J. Urol. 2010, 28:473-478.
17. Yancopoulos G.D., Davis S., Gale N.W., Rudge J.S., Wiegand S.J., Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000, 407:242-248.
18. Brown L.F., Berse B., Jackman R.W., Tognazzi K., Manseau E.J., Dvorak H.F., Senger D.R. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am. J. Pathol. 1993, 143:1255-1262.
19. Chikazawa M., Inoue K., Fukata S., Karashima T., Shuin T. Expression of angiogenesis-related genes regulates different steps in the process of tumor growth and metastasis in human urothelial cell carcinoma of the urinary bladder. Pathobiology 2008, 75:335-345.
20. Inoue K., Kamada M., Slaton J.W., Fukata S., Yoshikawa C., Tamboli P., Dinney C.P., Shuin T. The prognostic value of angiogenesis and metastasis-related genes for progression of transitional cell carcinoma of the renal pelvis and ureter. Clin. Cancer Res. 2002, 8:1863-1870.
21. Jain L., Vargo C.A., Danesi R., Sissung T.M., Price D.K., Venzon D., Venitz J., Figg W.D. The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. Mol. Cancer Ther. 2009, 8:2496-2508.
22. Renner W., Kotschan S., Hoffmann C., Obermayer-Pietsch B., Pilger E. A common 936C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J. Vasc. Res. 2003, 37:443-448.
23. Zhai R., Liu G., Asomaning K., Su L., Kulke M.H., Heist R.S., Nishioka N.S., Lynch T.J., Wain J.C., Lin X., Christiani D.C. Genetic polymorphisms of VEGF, interactions with cigarette smoking exposure and esophageal adenocarcinoma risk. Carcinogenesis 2008, 29:2330-2334.
24. Steffensen K.D., Waldstrøm M., Brandslund I., Jakobsen A. The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer. Gynecol. Oncol. 2010, 117:109-116.
25. Kim E.J., Jeong P., Quan C., Kim J., Bae S.C., Yoon S.J., Kang J.W., Lee S.C., Wee J.J., Kim W.J. Genotypes of TNF-alpha, VEGF, hOGG1, GSTM1, and GSTT1: useful determinants for clinical outcome of bladder cancer. Urology 2005, 65:70-75.
26. García-Closas M., Malats N., Real F.X., Yeager M., Welch R., Silverman D., Kogevinas M., Dosemeci M., Figueroa J., Chatterjee N., Tardón A., Serra C., Carrato A., García-Closas R., Murta-Nascimento C., Rothman N., Chanock S.J. Large-scale evaluation of candidate genes identifies associations between VEGF polymorphisms and bladder cancer risk. PLoS Genet. 2007, 3:e29.
27. Krippl P., Langsenlehner U., Renner W., Yazdani-Biuki B., Wolf G., Wascher T.C., Paulweber B., Weitzer W., Samonigg H. A common 936C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int. J. Cancer 2003, 106:468-471.
28. Liu L.Z., Jiang Y., Carpenter R.L., Jing Y., Peiper S.C., Jiang B.H. Role and mechanism of arsenic in regulating angiogenesis. PLoS ONE 2011, 6:e20858.
29. Hung R.Y., Chen G.G. Cigarette smoking, cyclooxygenase-2 pathway and cancer. Biochim. Biophys. Acta 2011, 1815:158-169.
30. Bao L., Shi H. Arsenite induces endothelial cell permeability increase through a reactive oxygen species-vascular endothelial growth factor pathway. Chem. Res. Toxicol. 2010, 23:1726-1734.
31. Costa F., Soares R. Nicotine, a pro-angiogenic factor. Life Sci. 2009, 84:785-790.
32. Pomerleau C.S., Pomerleau O.F., Snedecor S.M., Mehringer A.M. Defining a never-smoker: results from the nonsmokers survey. Addict. Behav. 2004, 29:1149-1154.
33. Chen C.H., Chiou H.Y., Hsueh Y.M., Chen C.J., Yu H.J., Pu Y.S. Clinico-pathological characteristics and survival outcome of arsenic related bladder cancer in Taiwan. J. Urol. 2009, 181:547-552.
34. Jean J.S., Jochen B., Chen C.J., Guo H.R., Liu C.W., Lin T.F., Chen Y.H. The Taiwan crisis: a showcase of the global arsenic problem. Arsenic in Environment 2010, vol. 3. CRC Press Taylor & Francis Group, Leiden, The Netherlands, p. 203.
35. Kalilani L., Atashili J. Measuring additive interaction using odds ratios. Epidemiol. Perspect. Innov. 2006, 3:5.
36. Cantor K.P., Lubin J.H. Arsenic, internal cancers, and issues in inference from studies of low-level exposures in human populations. Toxicol. Appl. Pharmacol. 2007, 222:252-257.
37. Hertz-Picciotto I., Smith A.H., Holtzman D., Lipsett M., Alexeeff G. Synergism between occupational arsenic exposure and smoking in the induction of lung cancer. Epidemiology 1992, 3:23-31.
38. Melkonian S., Argos M., Pierce B.L., Chen Y., Islam T., Ahmed A., Syed E.H., Parvez F., Graziano J., Rathouz P.J., Ahsan H. A prospective study of the synergistic effects of arsenic exposure and smoking, sun exposure, fertilizer use, and pesticide use on risk of premalignant skin lesions in Bangladeshi men. Am. J. Epidemiol. 2011, 173:183-191.
39. Bartoletti R., Cai T., Nesi G., Sardi I., Rizzo M., Qualitative quantitative analysis of angiogenetic factors in transitional cell bladder carcinoma: relationship with clinical course at 10 years follow-up. Oncol. Rep. 2005, 14:251-255.
40. Charlesworth P.J., Harris A.L. Mechanisms of disease: angiogenesis in urologic malignancies. Nat. Clin. Pract. Urol. 2006, 3:157-169.
41. Xu B., Feng N.H., Tong N., Wang Z.D., Zhang W., Wu H.F., Hua L.X. VEGF -460C>T polymorphism and cancer risk: a meta-analysis. Med. Oncol. 2010, 27:1031-1036.
42. Chen M.H., Tzeng C.H., Chen P.M., Lin J.K., Lin T.C., Chen W.S., Jiang J.K., Wang H.S., Wang W.S. VEGF -460T→ polymorphism and its association with VEGF expression and outcome to FOLFOX-4 treatment in patients with colorectal carcinoma. Pharmacogenom. J. 2011, 11:227-236.
43. Kim J.G., Sohn S.K., Chae Y.S., Cho Y.Y., Bae H.I., Yan G., Park J.Y., Lee M.H., Chung H.Y., Yu W. Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with gastric cancer. Ann. Oncol. 2007, 18:1030-1036.
44. Summers A.M., Coupes B.M., Brennan M.F., Ralph S.A., Short C.D., Brenchley P.E. VEGF -460 genotype plays an important role in progression to chronic kidney disease stage 5. Nephrol. Dial. Transplant. 2005, 20:2427-2432.
45. Lin J.M., Wan L., Tsai Y.Y., Lin H.J., Tsai Y., Lee C.C., Tsai C.H., Tseng S.H., Tsai F.J. Vascular endothelial growth factor gene polymorphisms in age-related macular degeneration. Am. J. Ophthalmol. 2008, 145:1045-1051.
46. Levy A.P., Levy N.S., Goldberg M.A. Hypoxia-inducible protein binding to vascular endothelial growth factor mRNA and its modulation by the von Hippel-Lindau protein. J. Biol. Chem. 1996, 271:25492-25497.
47. Stevens A., Soden J., Brenchley P.E., Ralph S., Ray D.W. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res. 2003, 63:812-816.